The most common adverse events of any grade were nausea ( 85 [ 64 % ] of 132 patients in the gefitinib group and 81 [ 61 % ] of 132 patients in the placebo group ) and decreased appetite ( 65 [ 49 % ] and 45 [ 34 % ] ) .